Health ❯Healthcare ❯Pharmaceuticals

Weight Loss Drugs

Wegovy Tirzepatide Zepbound Ozempic GLP-1 Receptor Agonists GLP-1 Medications Semaglutide Mounjaro Clinical Trials GLP-1 Agonists

10 ARTICLES

last mo.

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

Researchers are preparing human trials of letrozole and irinotecan after electronic health data linked the combo to lower Alzheimer’s risk, mindful of its side-effect profile

8 ARTICLES

2mo ago

NHS to Expand GP Prescriptions of Mounjaro for Weight Loss

10 ARTICLES

2mo ago

NHS Weight-Loss Jab Prescriptions Near Three Million as Experts Raise Lifelong Use Concerns

9 ARTICLES

3mo ago

Limited Access to Popular Weight-Loss Drugs Highlights Socioeconomic Disparities

3 ARTICLES

10mo ago

Supply and Cost Challenges Persist for Popular Weight-Loss Drugs

Particle.news

Weight Loss Drugs

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

NHS to Expand GP Prescriptions of Mounjaro for Weight Loss

NHS Weight-Loss Jab Prescriptions Near Three Million as Experts Raise Lifelong Use Concerns

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves

‘Ozempic Teeth’ Emerges as a Serious Dental Risk for Weight-Loss Drug Users

WHO to Endorse GLP-1 Weight-Loss Drugs, Calls for Global Access

FDA Seizes Counterfeit Ozempic in U.S. Supply Chain

Hims & Hers Expands Weight-Loss Offerings with New Medications

Novo Nordisk Acquires Chinese Obesity Drug After CagriSema Trial Disappointment

Taxpayer-Funded Weight-Loss Drugs Face Scrutiny Over High Prices

Never miss stories about

Weight Loss Drugs

Eli Lilly Expands Zepbound Access with New Doses and Lower Prices

FDA Ends Shortage of Tirzepatide, Restricts Compounded Weight-Loss Drugs

FDA Ends Shortage of Eli Lilly’s Weight-Loss Drug, Restricts Copycat Versions

Eli Lilly Partners with Ro to Expand Access to Lower-Cost Zepbound Vials

Dr. Oz Faces Scrutiny Over Conflicts of Interest in Medicare and Medicaid Role

Diabetes and Obesity Drugs Found to Protect Kidney Health

Government Plans Dominate Coverage for Costly Weight-Loss Drugs

New Weight Loss Drug Shows Promise Without Nausea

Limited Access to Popular Weight-Loss Drugs Highlights Socioeconomic Disparities

Supply and Cost Challenges Persist for Popular Weight-Loss Drugs

Never miss stories about

Weight Loss Drugs